Andrew S. Boyer - Feb 27, 2023 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
Executive Vice President
Signature
/s/ Denis Butkovic, Attorney-in-Fact
Stock symbol
AMRX
Transactions as of
Feb 27, 2023
Transactions value $
-$37,923
Form type
4
Date filed
3/1/2023, 03:30 PM
Previous filing
Jul 5, 2022
Next filing
Mar 3, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Options Exercise +31.7K +15.22% 240K Feb 27, 2023 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -$37.9K -17.6K -7.32% $2.16 222K Feb 27, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Options Exercise $0 -31.7K -50% $0.00 31.7K Feb 27, 2023 Class A Common Stock 31.7K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3 Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4 On February 27, 2020, the reporting person was granted 126,649 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Remarks:

Exhibit 24-Power of Attorney